Cadila Healthcare dips 8% as USFDA issues warning letter for Moraiya plant

The company said the warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will continue.

Shares of Cadila Healthcare slipped 8 per cent to Rs 234 on the BSE in the intra-day trade on Monday after the company received a warning letter from the US health regulator for its Moraiya formulation facility.

In a regulatory filing today, Cadila Healthcare said the Company has received a warning letter issued by the United States Food and Drug Administration (USFDA) relating to its Moraiya formulation facility.

However, the drug maker added the warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will